TY - JOUR
T1 - Deep sequencing of HPV16 genomes
T2 - A new high-throughput tool for exploring the carcinogenicity and natural history of HPV16 infection
AU - Cullen, Michael
AU - Boland, Joseph F.
AU - Schiffman, Mark
AU - Zhang, Xijun
AU - Wentzensen, Nicolas
AU - Yang, Qi
AU - Chen, Zigui
AU - Yu, Kai
AU - Mitchell, Jason
AU - Roberson, David
AU - Bass, Sara
AU - Burdette, Laurie
AU - Machado, Moara
AU - Ravichandran, Sarangan
AU - Luke, Brian
AU - Machiela, Mitchell J.
AU - Andersen, Mark
AU - Osentoski, Matt
AU - Laptewicz, Michael
AU - Wacholder, Sholom
AU - Feldman, Ashlie
AU - Raine-Bennett, Tina
AU - Lorey, Thomas
AU - Castle, Philip E.
AU - Yeager, Meredith
AU - Burk, Robert D.
AU - Mirabello, Lisa
N1 - Funding Information:
This study was funded by the Intramural Research Program of the Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health .
Publisher Copyright:
© 2015.
PY - 2015/12/1
Y1 - 2015/12/1
N2 - For unknown reasons, there is huge variability in risk conferred by different HPV types and, remarkably, strong differences even between closely related variant lineages within each type. HPV16 is a uniquely powerful carcinogenic type, causing approximately half of cervical cancer and most other HPV-related cancers. To permit the large-scale study of HPV genome variability and precancer/cancer, starting with HPV16 and cervical cancer, we developed a high-throughput next-generation sequencing (NGS) whole-genome method. We designed a custom HPV16 AmpliSeq™ panel that generated 47 overlapping amplicons covering 99% of the genome sequenced on the Ion Torrent Proton platform. After validating with Sanger, the current "gold standard" of sequencing, in 89 specimens with concordance of 99.9%, we used our NGS method and custom annotation pipeline to sequence 796 HPV16-positive exfoliated cervical cell specimens. The median completion rate per sample was 98.0%.Our method enabled us to discover novel SNPs, large contiguous deletions suggestive of viral integration (OR of 27.3, 95% CI 3.3-222, P=0.002), and the sensitive detection of variant lineage coinfections. This method represents an innovative high-throughput, ultra-deep coverage technique for HPV genomic sequencing, which, in turn, enables the investigation of the role of genetic variation in HPV epidemiology and carcinogenesis.
AB - For unknown reasons, there is huge variability in risk conferred by different HPV types and, remarkably, strong differences even between closely related variant lineages within each type. HPV16 is a uniquely powerful carcinogenic type, causing approximately half of cervical cancer and most other HPV-related cancers. To permit the large-scale study of HPV genome variability and precancer/cancer, starting with HPV16 and cervical cancer, we developed a high-throughput next-generation sequencing (NGS) whole-genome method. We designed a custom HPV16 AmpliSeq™ panel that generated 47 overlapping amplicons covering 99% of the genome sequenced on the Ion Torrent Proton platform. After validating with Sanger, the current "gold standard" of sequencing, in 89 specimens with concordance of 99.9%, we used our NGS method and custom annotation pipeline to sequence 796 HPV16-positive exfoliated cervical cell specimens. The median completion rate per sample was 98.0%.Our method enabled us to discover novel SNPs, large contiguous deletions suggestive of viral integration (OR of 27.3, 95% CI 3.3-222, P=0.002), and the sensitive detection of variant lineage coinfections. This method represents an innovative high-throughput, ultra-deep coverage technique for HPV genomic sequencing, which, in turn, enables the investigation of the role of genetic variation in HPV epidemiology and carcinogenesis.
KW - HPV epidemiology
KW - HPV genomics
KW - HPV16
UR - http://www.scopus.com/inward/record.url?scp=84947930704&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84947930704&partnerID=8YFLogxK
U2 - 10.1016/j.pvr.2015.05.004
DO - 10.1016/j.pvr.2015.05.004
M3 - Article
AN - SCOPUS:84947930704
SN - 2405-8521
VL - 1
SP - 3
EP - 11
JO - Papillomavirus Research
JF - Papillomavirus Research
ER -